Stockscreener 앱 받기
2.4315
6.90%
-0.1785
전일 마감가:
$2.61
열려 있는:
$2.64
하루 거래량:
1.07M
Relative Volume:
0.54
시가총액:
$172.95M
수익:
$20.76M
순이익/손실:
$-132.49M
주가수익비율:
-0.9107
EPS:
-2.67
순현금흐름:
$-108.55M
1주 성능:
-8.30%
1개월 성능:
+7.05%
6개월 성능:
+39.66%
1년 성능:
-56.68%
1일 변동 폭
$2.37
$2.6495
1주일 범위
$2.37
$2.6738
52주 변동 폭
$1.085
$6.52
C 4 Therapeutics Inc Stock (CCCC) Company Profile
명칭
C 4 Therapeutics Inc
전화
(617) 231-0700
주소
490 ARSENAL WAY, WATERTOWN
CCCC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.43 | 242.90M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.63 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.13 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.19 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.23 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.89 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-15 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Equal-Weight |
| 2024-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-13 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-04-28 | 개시 | Credit Suisse | Underperform |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-10 | 개시 | JP Morgan | Overweight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-11-23 | 개시 | BofA Securities | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-27 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-27 | 개시 | Jefferies | Buy |
모두보기
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Inc. stock trend forecastNew Guidance & High Accuracy Trade Signal Alerts - newser.com
Volatility clustering patterns for C4 Therapeutics Inc.Earnings Overview Summary & Safe Entry Point Identification - newser.com
Will earnings trigger a reversal in C4 Therapeutics Inc.Product Launch & Low Risk Investment Opportunities - newser.com
C4 Therapeutics Inc Stock Analysis and ForecastSupport Zone Identification & Investor Community Interactions - earlytimes.in
C4 Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in C4 The - GuruFocus
How strong is C4 Therapeutics Inc. stock balance sheet2025 Buyback Activity & Technical Pattern Based Buy Signals - fcp.pa.gov.br
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
What hedge fund activity signals for C4 Therapeutics Inc. stockMarket Movers & Low Drawdown Investment Ideas - fcp.pa.gov.br
Ptc therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
C4 Therapeutics Inc. stock retracement – recovery analysisMarket Performance Summary & Proven Capital Preservation Tips - newser.com
How C4 Therapeutics Inc. stock benefits from strong dollarJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Full technical analysis of C4 Therapeutics Inc. stockQuarterly Profit Report & Real-Time Volume Analysis Alerts - newser.com
C4 Therapeutics (NASDAQ:CCCC) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
How C4 Therapeutics Inc. stock reacts to oil pricesEarnings Overview Summary & Community Consensus Picks - newser.com
C4 Therapeutics (CCCC) Expected to Announce Earnings on Thursday - MarketBeat
Applying chart zones and confluence areas to C4 Therapeutics Inc.2025 Big Picture & Breakout Confirmation Trade Signals - newser.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Live market analysis of C4 Therapeutics Inc.2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
Candlestick signals on C4 Therapeutics Inc. stock todayJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Will C4 Therapeutics Inc. stock benefit from commodity pricesEarnings Risk Report & Low Risk High Win Rate Stock Picks - Trung tâm Dự báo KTTV quốc gia
Will C4 Therapeutics Inc. stock maintain momentum in 20252025 Price Targets & Community Consensus Trade Alerts - Trung tâm Dự báo KTTV quốc gia
CEO Moves: Will C4 Therapeutics Inc. stock maintain momentum in 2025Weekly Profit Analysis & Weekly Consistent Profit Watchlists - Trung tâm Dự báo KTTV quốc gia
C4 Therapeutics Lines Up $125 Million To Fund Cancer Trials - Finimize
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
C4 Therapeutics Announces Stock and Warrants Offering - TipRanks
Revenues Working Against C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Share Price Following 38% Dive - 富途牛牛
C4 Therapeutics (CCCC) to Raise $125M Through Stock and Warrant Offering - GuruFocus
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering - Investing News Network
C4 Therapeutics, Inc. Announces $125 Million Underwritten Offering to Advance Cemsidomide Multiple Myeloma Development - Quiver Quantitative
$125M Upfront — C4 Therapeutics Prices Offering to Fund Cemsidomide Trials; May Reach $349.7M - Stock Titan
C4 Therapeutics Presents Phase 1 Trial Data - TipRanks
C4 Therapeutics, Inc. Presents Phase 1 Trial Data for Cemsidomide - TradingView
C4 Therapeutics prices equity deal; warrants could lift net to $341.7M - Stock Titan
C 4 Therapeutics Inc (CCCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
1.56%
자본화:
|
볼륨(24시간):